(Q40923280)

24 September 2017

title

PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials (English)

1 reference

24 September 2017

Kristopher J Swiger

1

1 reference

24 September 2017

Seth S Martin

series ordinal

2

1 reference

24 September 2017

publication date

1 June 2015

1 reference

24 September 2017

1 reference

24 September 2017

volume

38

1 reference

24 September 2017

issue

6

1 reference

24 September 2017

page(s)

519-526

1 reference

https://scigraph.springernature.com/pub.10.1007/s40264-015-0296-6

24 September 2017

exact match

0 references

cites work

Statin-associated adverse cognitive effects: survey results from 171 patients.

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Brain cholesterol: long secret life behind a barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Hypolipidemic drugs can change the composition of rat brain lipids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

LDL cholesterol: the lower the better

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Regulation of the mevalonate pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Possible role of vascular risk factors in Alzheimer's disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Long-term effects of secondary prevention on cognitive function in stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Plasma lipids and cerebral small vessel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

The controversies of statin therapy: weighing the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Statins and cognitive function: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Cochrane review on 'Statins for the treatment of dementia'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Cognitive effects of statin medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Non-cardiovascular effects associated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Cognitive impairment and outcomes in older adult survivors of acute myocardial infarction: findings from the translational research investigating underlying disparities in acute myocardial infarction patients' health status registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Volume reduction of the entorhinal cortex in subjective memory impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

Lipid lowering with PCSK9 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40264-015-0296-6

PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population

21 January 2018

1 reference

12 December 2020

Cardiology patient page. Statin intolerance

1 reference

12 December 2020

Oxidative stress and age-related neuronal deficits

1 reference

12 December 2020

Statin therapy and cognition

1 reference

12 December 2020

Statins for the treatment of dementia

1 reference

12 December 2020

N-of-1 (single-patient) trials for statin-related myalgia.

1 reference

12 December 2020

Blood-brain barrier permeability is markedly decreased in cholestasis in the rat.

1 reference

12 December 2020

10.1007/S40264-015-0296-6

Identifiers

DOI

1 reference

Dimensions Publication ID

24 September 2017

1015836652

0 references

1 reference